AZILECT DIN 02284642
Status: Marketed
Holder: TEVA CANADA LIMITED
Molecule: RASAGILINE (RASAGILINE MESYLATE)
Available to quote
Health Canada record
| Active ingredient(s) | RASAGILINE (RASAGILINE MESYLATE) 0.5 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N04BD02 RASAGILINE |
| Original market date | 14-Sep-2006 |
| Current status date | 03-Jun-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Teva Canada Limited — licence 101810, currently licensed, last inspection rating C (2025-03-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RASAGILINE (RASAGILINE MESYLATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02514540 | AG-RASAGILINE | ANGITA PHARMA INC. | Tablet | RASAGILINE (RASAGILINE MESYLATE) 1 MG | Approved |
| 02514532 | AG-RASAGILINE | ANGITA PHARMA INC. | Tablet | RASAGILINE (RASAGILINE MESYLATE) 0.5 MG | Approved |
| 02404680 | APO-RASAGILINE | APOTEX INC | Tablet | RASAGILINE (RASAGILINE MESYLATE) 0.5 MG | Marketed |
| 02404699 | APO-RASAGILINE | APOTEX INC | Tablet | RASAGILINE (RASAGILINE MESYLATE) 1 MG | Marketed |
| 02489139 | ASN-RASAGILINE | ASCEND LABORATORIES LTD | Tablet | RASAGILINE (RASAGILINE MESYLATE) 1 MG | Approved |
| 02489120 | ASN-RASAGILINE | ASCEND LABORATORIES LTD | Tablet | RASAGILINE (RASAGILINE MESYLATE) 0.5 MG | Approved |
| 02284650 | AZILECT | TEVA CANADA LIMITED | Tablet | RASAGILINE (RASAGILINE MESYLATE) 1 MG | Marketed |
| 02491974 | JAMP RASAGILINE | JAMP PHARMA CORPORATION | Tablet | RASAGILINE (RASAGILINE MESYLATE) 0.5 MG | Marketed |
| 02491982 | JAMP RASAGILINE | JAMP PHARMA CORPORATION | Tablet | RASAGILINE (RASAGILINE MESYLATE) 1 MG | Marketed |
| 02533723 | MINT-RASAGILINE | MINT PHARMACEUTICALS INC | Tablet | RASAGILINE (RASAGILINE MESYLATE) 0.5 MG | Approved |
| 02533731 | MINT-RASAGILINE | MINT PHARMACEUTICALS INC | Tablet | RASAGILINE (RASAGILINE MESYLATE) 1 MG | Approved |
| 02418444 | TEVA-RASAGILINE | TEVA CANADA LIMITED | Tablet | RASAGILINE (RASAGILINE MESYLATE) 1 MG | Marketed |
| 02418436 | TEVA-RASAGILINE | TEVA CANADA LIMITED | Tablet | RASAGILINE (RASAGILINE MESYLATE) 0.5 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 26005 | 2021-06-03 | New Drug Submission (NDS) | CHANGE IN PRODUCT OWNERSHIP |
| 16340 | 2014-11-24 | Supplement to a New Drug Submission (SNDS) | EXTENSION OF THE INDICATION TO INCLUDE USE AS ADJUNCT THERAPY TO DOPAMINE AGONISTS |
| 8211 | 2006-08-17 | New Drug Submission (NDS) |